Figure S2 from Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial

Kaplan-Meier analyses of PFS for patients with normal and elevated ({greater than or equal to}7 pg/ml) baseline IL-6 levels.</p

Figure S3 from Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial

Impact of the IL-6 cutoff level on progression-free survival (A) and overall survival (B).</p

Figure S1 from Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial

Kaplan-Meier curves for progression-free survival in subgroups.</p

Figure S4 from Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial

Dynamics of IL-6 levels in the two treatment groups at different time points (A) and comparison of the IL-6 levels between the two arms at each time point (B).</p